Amphastar Pharmaceuticals, Inc.

AMPHNASDAQHealthcare● Active

$19.39

$-0.35(-1.77%)

Market Cap$854961699

P/E Ratio—

52W High$31.26

52W Low$16.65

Avg Volume610K

Open$19.75

Beta0.90

Overview

Amphastar Pharmaceuticals, Inc. (AMPH) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

AMPH · free cash flow · updated Jun 8, 2026

Core FCF metrics

AMPH · FCF · TTM · margin & CAGR

Free cash flow was $121.2M for FY2025 (fiscal year ending 2025-12-31), down 29.7% year-over-year The FCF margin was 16.8%. Five-year CAGR stands at +38.9%.

FY2025 Free Cash Flow$121.2M▼ -29.7% YoY

Trailing 12M (TTM)$135.2Mtrailing 4 quarters sum

FCF Margin16.8%$121.2M ÷ revenue

3-Year CAGR+23.0%FY2022 → FY2025

5-Year CAGR+38.9%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

AMPH · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$156.1M(35M)$121.2M▼ 29.7%16.8%

FY2024$213.4M(41M)$172.3M▲ +18.6%23.6%

FY2023$183.5M(38M)$145.3M▲ +123.1%22.6%

FY2022$89.2M(24M)$65.1M▼ 7.6%13.1%

FY2021$98.0M(27M)$70.5M▲ +201.3%16.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

AMPH · P/FCF · FCF yield · FCF per share

Amphastar Pharmaceuticals, Inc. (AMPH) trades at a FCF yield of 15.71% and a price-to-free-cash-flow ratio of 6.7x. FCF per share stands at $2.89, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

15.71%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$2.89

TTM FCF ÷ Shares Outstanding

Price / FCF

x6.7

Share Price ÷ FCF per Share

EV / FCF (TTM)

x10.2

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

AMPH · cash flow statement · operating / investing / financing

For FY2025, Amphastar Pharmaceuticals, Inc. generated $156.1M in operating cash flow and spent 35M in capital expenditures, yielding $121.2M in free cash flow.

Operating Activities

+$156.1M

Cash from core business operations

2025-12-31

Investing Activities

−$70.3M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$67.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($156.1M) − |CapEx| (35M) = FCF ($121.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

AMPH vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Amphastar Pharmaceuticals, Inc.YOU

AMPH

$121.2M-29.7%16.8%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Amphastar Pharmaceuticals, Inc. (AMPH) reported free cash flow of $121.2M for FY2025 (fiscal year ending 2025-12-31), down 29.7% year-over-year. The FCF margin was 16.8%.

Based on available data, Amphastar Pharmaceuticals, Inc. has maintained positive free cash flow for at least 12 fiscal year(s). FCF peaked at $172.3M in FY2024. The 5-year CAGR stands at +38.9%.

Amphastar Pharmaceuticals, Inc.'s FCF yield is 15.71% and price-to-FCF ratio is 6.7x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

AMPH free cash flow · 8 questions

Amphastar Pharmaceuticals, Inc. free cash flow was $121.2M for FY2025, down 29.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $135.2M.

AMPH free cash flowAMPH FCFAMPH FCF 2025AMPH free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Amphastar Pharmaceuticals, Inc. · Amphastar Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026